<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951882</url>
  </required_header>
  <id_info>
    <org_study_id>2020-592</org_study_id>
    <nct_id>NCT04951882</nct_id>
  </id_info>
  <brief_title>Application of hUC-MSCs in Treating Acute Lung Injury: a Single Center Prospective Clinical Research</brief_title>
  <official_title>Transplatation of Human Umbilcal Cord Derived Mesenchyamal Stem Cells in Acute Lung Injury: a Single Center Prospective Clinical Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients suffered from acute lung ininjury (200&lt;PaO2/FiO2 ≤ 300) will be divided into two&#xD;
      groups: MSCs-treated group: patients are treated by intravenous injection of hUC-MSCs&#xD;
      suspention ; control group: patients were treated with vehicle(Albumin) . The standard&#xD;
      Therapies of acute lung injury were the same in both groups. In the following-up days, all&#xD;
      the patients were monitored by the same items to evaluate the therapeutic effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>Day 3</time_frame>
    <description>Oxygenation index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>Day 7</time_frame>
    <description>Oxygenation index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>Day 14</time_frame>
    <description>Oxygenation index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>Day 28</time_frame>
    <description>Oxygenation index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the days of ventialtion and hospital stay</measure>
    <time_frame>Day 3</time_frame>
    <description>the length of ventilation and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the days of ventialtion and hospital stay</measure>
    <time_frame>Day 7</time_frame>
    <description>the length of ventilation and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the days of ventialtion and hospital stay</measure>
    <time_frame>Day 14</time_frame>
    <description>the length of ventilation and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the days of ventialtion and hospital stay</measure>
    <time_frame>Day 28</time_frame>
    <description>the length of ventilation and hospital stay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 1</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 7</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 14</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 28</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-8</measure>
    <time_frame>Day 1</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-8</measure>
    <time_frame>Day 7</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-8</measure>
    <time_frame>Day 14</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-8</measure>
    <time_frame>Day 28</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-a</measure>
    <time_frame>Day 3</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-a</measure>
    <time_frame>Day 7</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-a</measure>
    <time_frame>Day 14</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-a</measure>
    <time_frame>Day 28</time_frame>
    <description>inflammatory factors</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>hUC-MSCs treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-cell therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human derived umbilical cord derived mesenchymal stem cells</intervention_name>
    <description>intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells</description>
    <arm_group_label>hUC-MSCs treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.≤ 3 days (72h)&#xD;
&#xD;
          -  2.Age ≥18 years, ≤65 years&#xD;
&#xD;
          -  3.200&lt;PaO2/FiO2 ≤ 300&#xD;
&#xD;
          -  4.Chest X-ray/chest CT : infiltrates of both lungs&#xD;
&#xD;
          -  5.Need assisted ventilation (ventilation or high flow oxygen therapy)&#xD;
&#xD;
          -  6.No left heart failure, pulmonary edema&#xD;
&#xD;
          -  7.Agree to participate and signe an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Life expectancy &lt;3 months due to non-respiratory failure&#xD;
&#xD;
          -  2.Patients receiving extracorporeal membrane oxygenation support therapy(ECMO),high&#xD;
             frequency oscillatory ventilation&#xD;
&#xD;
          -  3.History of HIV, malignant tumors, or impaired immune function&#xD;
&#xD;
          -  4.Patients accepted major surgery in the past 14 days (such as tumor removal,&#xD;
             thoracotomy, heart surgery, abdominal surgery, intracranial surgery, or surgery for&#xD;
             more than 3 hours, etc.)&#xD;
&#xD;
          -  5.Pregnancy&#xD;
&#xD;
          -  6.Have a serious concomitant disease&#xD;
&#xD;
          -  7.Unable to follow-up&#xD;
&#xD;
          -  8.History of severe allergic reactions or allergy to saline and serum&#xD;
&#xD;
          -  9.Already participated in another clinical study within 12 weeks&#xD;
&#xD;
          -  10.Pulmonary edema caused by other underlying diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SAHZU</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongan Xu</last_name>
      <phone>13757164833</phone>
      <email>xuyongan2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

